Who’s that with Mairtin??? Of course it’s Katherine ThomasBREAKING NEWS: The staff and management of a Co Donegal business are celebrating being named the No1 in Ireland.Kelly’s Centra Mountain Top in Letterkenny has been named National Centra Convenience Store of the Year 2015.This prestigious award recognises all that is good about community retailing from investment in local products, involvement in the local charities. This is the second year Kelly’s centra mountain top was shortlisted to the final 10 – reduced down from 463 in the competition.The only Donegal store to have got this far, Kelly’s Centra won the national convenience beating off stiff competition from stores all around the countryOwner Mairtin Kelly said: “It’s all about the people. I am very proud to have picked up this award on behalf of them and my customers.“I want to pay particular tribute to my managers David Bonner and Lee O Donnell who only took up the roles as store managers in 2014. “They’ve really work tirelessly to deliver the excellent standards our customers have became accustomed to.“With more store innovations planned in 2015 by the store Kelly’s Centra continues to lead the way in retailing not only in Letterkenny but now in Ireland.”Winners: The Kelly’s Centra Mountain Top teamBREAKING NEWS: KELLY’S CENTRA MOUNTAIN TOP NAMED NO1 STORE IN THE COUNTRY 2015 was last modified: February 3rd, 2015 by John2Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:2015award winnersKelly’s CentraletterkennyMountain Top
Aug 22 2018Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Sonata® Sonography-Guided Transcervical Fibroid Ablation (Sonata) System.The Sonata System combines a breakthrough integrated technology which is the first and only intrauterine ultrasound system with a proprietary radiofrequency ablation device, providing a transcervical, incision-free, uterus-preserving treatment for uterine fibroids.With an estimated volume of more than 1 million annual global fibroid procedures, Gynesonics projects a $3 billion-4 billion global market opportunity for its Sonata System for the treatment of uterine fibroids, including a market opportunity of more than $1 billion in the U.S. alone.”We are excited to announce FDA clearance of our Sonata System. This is an essential milestone for Gynesonics in our mission to bring this transformational technology for the treatment of uterine fibroids to women,” said President and CEO Christopher Owens. “The patient outcomes achieved with Sonata demonstrate its potential to become a new standard of care in fibroid treatment, providing important patient benefits as compared to invasive surgery. Clinical trial outcomes show that Sonata provides a significant and durable improvement in symptoms with more than half the women returning to normal activities within 24 hours.”In a published survey of 968 women affected by fibroids (American Journal of Obstetrics and Gynecology, 2013), the key findings include:Related StoriesTransobturator sling surgery shows promise for stress urinary incontinenceSleep disorders in patients with low back pain linked to increased healthcare visits, costsApplication of machine learning methods to healthcare outcomes research 79% of women want to avoid invasive surgery; Affected women wait an average of 3.6 years before being treated; Most women, regardless of desire for future fertility, want to preserve their uterus. Source:https://gynesonics.com/ “The published survey results show that women are looking for new options to address this widespread condition, they want to preserve their uterus and they wish to avoid invasive surgery, including hysterectomy,” Owens added. “Sonata is the only system that can treat the vast majority of all fibroids with a transcervical, incision-free, uterus-preserving approach. Current transcervical options are limited to treatment of a small portion of the total fibroid market by comparison.”According to medical literature, about 70-80 percent of women in the U.S. will develop uterine fibroids by age 50, with a significant proportion of women having symptoms, many of which can be severe and debilitating. In addition, according to the New England Journal of Medicine, approximately 200,000 hysterectomies are performed in the United States each year because of symptomatic fibroids.Owens added that the company exceeded the FDA-specified 12-month primary endpoint performance requirements for the Sonata System in the SONATA pivotal IDE clinical trial used to support the FDA regulatory 510(k) filing. The co-primary endpoints included a significant reduction in bleeding and a high rate of freedom from surgical reintervention due to heavy menstrual bleeding (HMB). The safety outcomes were also favorable, including zero device-related adverse events reported in the 147-patient trial.